secwatch.observer — SEC 8-K summary
======================================

Issuer:     Canton Strategic Holdings, Inc. (CNTN)
CIK:        0001861657
Form:       8-K
Filed at:   2023-07-11T23:59:59+00:00
Accession:  0001493152-23-024270
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hillstream BioPharma signs ABSI license for ErbB2/ErbB3; appoints Sireesh Appajosyula as COO
--------------------------------------------------------------------------------

- Licensed exclusive rights from ABSI to develop antibodies targeting ErbB2 (Her2) and ErbB3 in all human/animal diseases worldwide.
- Will issue $250k in common stock to ABSI within 30 days; milestones up to $8.25M; royalties low-to-mid single digits on net sales.
- Appointed director Sireesh Appajosyula as COO effective July 6, 2023; base salary $400k, annual bonus target 50% of base.
- Amended CEO Randy Milby's employment: base $500k, bonus target 60%, severance period increased to 18 months on certain terminations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861657/000149315223024270/0001493152-23-024270-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861657/000149315223024270/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-024270

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer